If your child/patient has recently started showing symptoms and has been diagnosed with moderate to severe PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) or PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections), they may qualify to participate in a Phase III Clinical trial which is studying how well IVIG might help PANS/PANDAS patients. Study-related travel expenses are provided for participating treatment centers.
This is a randomized, double-blind, placebo-controlled superiority study spanning about 6 months.